HOYA Corporation

7741.T
Medical Instruments & Supplies
2026/03/02 Updated
Market Cap: $61.3B (¥9.6T)
Stock Price: $181.18 (¥28,265)
Exchange Rate: 1 USD = ¥156.01

Notice Regarding Auxiliary Participation in Shareholder Derivative Lawsuit

The Company has decided to participate as an auxiliary defendant in the shareholder derivative lawsuit and will appropriately counter the plaintiff shareholders' claims as they are judged to be unfounded.

Importance:
Page Updated: March 2, 2026
IR Disclosure Date: March 2, 2026

Key Figures

  • Number of Auxiliary Participating Defendants: 7 (1 former director and representative executive officer, 5 former outside directors, 1 current director and representative executive officer)
  • Decision Date of Auxiliary Participation: 2026-03-02
  • Audit Committee Consent: Unanimous

AI要約

Overview of Auxiliary Participation in Shareholder Derivative Lawsuit

Following the announcement dated February 24, 2026, regarding the shareholder derivative lawsuit, the Company has decided to participate as an auxiliary defendant in this lawsuit on behalf of seven individuals: one former director and representative executive officer, five former outside directors, and one current director and representative executive officer. After investigation, it has been determined that these seven defendants bear no liability for compensation under Article 462, Paragraph 1 of the Companies Act nor liability for breach of duty under Article 423, Paragraph 1, and that the plaintiff shareholders’ claims are without merit. As an auxiliary participant, the Company will appropriately engage in the litigation process and counter the plaintiff’s claims.

Future Response

The Company has obtained the unanimous consent of all Audit Committee members regarding this lawsuit and has declared that it will promptly disclose any information that should be disclosed in the future. As the lawsuit progresses, the Company intends to appropriately disclose important information that may affect investors.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.